SARS-CoV-2 Neutralizing Antibody Test
Vaperon ™ SARS-CoV-2 Neutralizing Antibody Rapid Detection Kit is intended for the confirmation of the individual's adaptive immune response to SARS-CoV-2, as a measurement to the protesting ability resulted from COVID-19 vaccine.
Vaperon™ SARS-CoV-2 Neutralizing Antibody Rapid Detection Kit (Colloidal Gold) is an immuno-chromatographic assay kit, used to visually detect the total neutralizing antibodies in human serum, plasma or whole blood specimen with high sensitivity and specificity.
Vaperon™ SARS-CoV-2 Neutralizing Antibody Rapid Detection Kit is intended for identifying individuals with adaptive immune response to SARS-CoV-2, indicating recent or prior infection or vaccination. The SARS-COV-2 Neutralizing antibody test kit should NOT be used to diagnose acute SARS-CoV-2 infection.
Why Neutralizing Antibodies Matter
Neutralizing antibodies are the subpopulation of the antibodies secreted by the immune cells after the invasion of the COVID-19 or injection of vaccine, which are specific to the receptor-binding domain (RBD) of the SARS-COV-2 virus, and can block the cellular infiltration and viral replication. In this sense, the neutralizing antibodies, either incurred by virus or vaccination, is the first ladder of "soldiers" in human body, which fight against the COVID-19 virus.
Vaperon™ SARS-COV-2 Neutralizing antibody kit
Vaperon™ is a new trade name, which Atlas Link Technology Co., Ltd specially adopted for the new SARS-COV-2 Neutralizing antibody detection kit; brand name application in process.
Novel coronavirus pneumonia (Coronavirus Disease 2019, short as COVID-19) is an infectious disease caused by SARS-COV-2 infection. On February 11, 2020, the International Committee for Taxonomy of Viruses (ICTV) renamed the virus SARS-CoV-2.
SARS-CoV-2 has several structural proteins including spike (S), envelope (E), membrane (M) and nucleocapsid (N). The spike protein (S) contains a receptor-binding domain (RBD), which is responsible for recognizing the cell surface receptor, angiotensin converting enzyme-2 (ACE2). It is found that the RBD of the SARS-CoV-2 S protein strongly interacts with the human ACE2 receptor, leading to endocytosis into the host cells of the deep lung and viral replication.